| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Operating lease liabilities | 17 | - |
| Net cash used in operating activities | -31,313 | -19,980 |
| Purchase of short-term investments | 34,523 | - |
| Purchase of property and equipment | 183 | - |
| Net cash used in investing activities | -34,706 | - |
| Proceeds from the issuance of convertible promissory notes (including 3,402 and 9,993 from a related party), net of issuance costs | 7,500 | 7,500 |
| Cash acquired in connection with the merger | 102,113 | 102,113 |
| Payment of deferred transaction costs and issuance costs | 2,346 | 2,346 |
| Net cash provided by financing activities | 107,267 | 107,267 |
| Net increase (decrease) in cash and cash equivalents and restricted cash | 41,248 | 87,287 |
| Cash and cash equivalents at beginning of period | 1,639 | - |
| Cash and cash equivalents at end of period | 42,887 | - |
Kalaris Therapeutics, Inc. (KLRS)
Kalaris Therapeutics, Inc. (KLRS)